These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33962658)

  • 21. Aborted Cardiac Arrest in LQT2 Related to Novel
    Bileišienė N; Barysienė J; Mikštienė V; Preikšaitienė E; Marinskis G; Keževičiūtė M; Utkus A; Aidietis A
    Medicina (Kaunas); 2021 Jul; 57(7):. PubMed ID: 34357002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome].
    Fang P; Lian J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Feb; 33(1):101-4. PubMed ID: 26829745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced hERG block and long QT syndrome.
    Witchel HJ
    Cardiovasc Ther; 2011 Aug; 29(4):251-9. PubMed ID: 20406244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon.
    Choe CU; Schulze-Bahr E; Neu A; Xu J; Zhu ZI; Sauter K; Bähring R; Priori S; Guicheney P; Mönnig G; Neapolitano C; Heidemann J; Clancy CE; Pongs O; Isbrandt D
    Hum Mol Genet; 2006 Oct; 15(19):2888-902. PubMed ID: 16923798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
    Ficker E; Obejero-Paz CA; Zhao S; Brown AM
    J Biol Chem; 2002 Feb; 277(7):4989-98. PubMed ID: 11741928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. R534C mutation in hERG causes a trafficking defect in iPSC-derived cardiomyocytes from patients with type 2 long QT syndrome.
    Mesquita FCP; Arantes PC; Kasai-Brunswick TH; Araujo DS; Gubert F; Monnerat G; Silva Dos Santos D; Neiman G; Leitão IC; Barbosa RAQ; Coutinho JL; Vaz IM; Dos Santos MN; Borgonovo T; Cruz FES; Miriuka S; Medei EH; Campos de Carvalho AC; Carvalho AB
    Sci Rep; 2019 Dec; 9(1):19203. PubMed ID: 31844156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and functional characterization of the human ether-a-go-go-related gene Q738X mutant associated with hereditary long QT syndrome type 2.
    Han SN; Yang SH; Zhang Y; Sun XY; Duan YY; Hu XJ; Fan TL; Huang CZ; Yang G; Zhang Z; Zhang L
    Int J Mol Med; 2014 Sep; 34(3):810-5. PubMed ID: 24993425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of a human embryonic stem cell line (WAe009-A-43) carrying a Long QT syndrome related mutation in KCNH2 gene.
    Wu X; Zhao Y; Wang X
    Stem Cell Res; 2020 Oct; 48():101976. PubMed ID: 32911324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling the long QT syndrome with induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Zwi-Dantsis L; Caspi O; Winterstern A; Feldman O; Gepstein A; Arbel G; Hammerman H; Boulos M; Gepstein L
    Nature; 2011 Mar; 471(7337):225-9. PubMed ID: 21240260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
    Anderson CL; Delisle BP; Anson BD; Kilby JA; Will ML; Tester DJ; Gong Q; Zhou Z; Ackerman MJ; January CT
    Circulation; 2006 Jan; 113(3):365-73. PubMed ID: 16432067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. hERG 1b is critical for human cardiac repolarization.
    Jones DK; Liu F; Vaidyanathan R; Eckhardt LL; Trudeau MC; Robertson GA
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):18073-7. PubMed ID: 25453103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
    De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hERG channel activator, RPR260243, enhances protective
    Shi YP; Pang Z; Venkateshappa R; Gunawan M; Kemp J; Truong E; Chang C; Lin E; Shafaattalab S; Faizi S; Rayani K; Tibbits GF; Claydon VE; Claydon TW
    Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H251-H261. PubMed ID: 32559136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. Human Ether-à-go-go-Related Gene.
    Roti EC; Myers CD; Ayers RA; Boatman DE; Delfosse SA; Chan EK; Ackerman MJ; January CT; Robertson GA
    J Biol Chem; 2002 Dec; 277(49):47779-85. PubMed ID: 12270925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
    Mehta A; Ramachandra CJA; Singh P; Chitre A; Lua CH; Mura M; Crotti L; Wong P; Schwartz PJ; Gnecchi M; Shim W
    Eur Heart J; 2018 Apr; 39(16):1446-1455. PubMed ID: 29020304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
    Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
    Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Interdomain KCNH2 Mutation Produces an Intermediate Long QT Syndrome.
    Osterbur ML; Zheng R; Marion R; Walsh C; McDonald TV
    Hum Mutat; 2015 Aug; 36(8):764-73. PubMed ID: 25914329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.